8-K: PetMed Express Reports Q4 and FY26 Financial Results

PetMed Express announced its fourth quarter and fiscal year 2026 financial results, reporting a decrease in net sales and a reduced net loss for the quarter, while the full year saw a significant increase in net loss.

Summary

• For the fourth quarter ended March 31, 2026, PetMed Express reported net sales of $42.8 million, a decrease of 15.6% compared to the prior year period, primarily due to a decline in prescription medication sales.
• The company reported a net loss of $4.1 million, or $(0.19) per diluted share, for the fourth quarter, an improvement from a net loss of $11.6 million, or $(0.56) per diluted share, in the prior year period.
• For the full fiscal year 2026, net sales decreased by 21.1% to $179.0 million compared to $227.0 million in the prior year, also driven by a decline in prescription medication sales.
• The full fiscal year 2026 resulted in a net loss of $57.3 million, or $(2.74) per diluted share, a significant increase from a net loss of $6.3 million, or $(0.30) per diluted share, in the prior year.
• Adjusted EBITDA for the fourth quarter was $(2.8) million, compared to $(1.9) million in the prior year period.
• Adjusted EBITDA for the full fiscal year 2026 was $(15.4) million, compared to $0.7 million for the prior year.
• The company received unsolicited, non-binding acquisition proposals in December 2025 ranging from $4.00 to $4.25 per share, but the Board determined not to proceed with these proposals after evaluating alternatives and soliciting other interest.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to significant declines in sales and a substantial increase in net loss for the full fiscal year, despite some sequential improvement in the fourth quarter.

Positives

• Modest sequential quarterly increase in fourth quarter net sales, indicating positive momentum.
• Reduced net loss in the fourth quarter of fiscal 2026 to $4.1 million from $11.6 million in the prior year period.
• Lower general and administrative expenses contributed to the improved net loss in the fourth quarter.
• Higher interest income in the fourth quarter.
• Lower provision for income taxes in the fourth quarter.
• Strategic, operational, and technology initiatives completed in fiscal 2026 are expected to reduce the cost structure and form a foundation for future growth.
• Plans to focus on operational excellence, driving sustainable long-term results, and delivering shareholder value.
• Intent to improve customer retention and expand market footprint through B2B relationships and white-label fulfillment services.

Negatives

• Net sales decreased by 15.6% in the fourth quarter and 21.1% for the full fiscal year 2026.
• Significant increase in net loss for the full fiscal year 2026 to $57.3 million from $6.3 million in the prior year.
• Full year net loss primarily driven by a goodwill impairment charge of $26.7 million, increased stock-based compensation expense, increased professional fees and executive severance costs ($4.5 million related to whistleblower investigation).
• Adjusted EBITDA worsened in the fourth quarter to $(2.8) million from $(1.9) million and significantly worsened for the full year to $(15.4) million from $0.7 million.
• Cash and cash equivalents decreased from $54.7 million to $21.4 million.
• Net cash used in operating activities was $(28.4) million for the full fiscal year 2026.

Risks

• Factors that could cause results to differ materially from forward-looking statements include those set forth in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections in the Company's Annual Report on Form 10-K for the year ended March 31, 2026.
• Future results may be impacted by other risk factors listed in the Company's filings with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and periodic filings on Form 8-K.
• The company is continuing to operate as an independent, publicly traded company after deciding not to proceed with unsolicited acquisition proposals.

Future Outlook

The company is focusing on stabilizing its core business, strengthening its foundation for long-term value creation through strategic, operational, and technology initiatives. They intend to improve customer retention and expand market footprint via B2B relationships and white-label fulfillment services. The Board remains open to considering future inbound indications of interest for a potential transaction.

Management Comments

• "We are pleased to report a modest sequential quarterly increase in fourth quarter net sales, demonstrating positive momentum as we close out the year."
• "Throughout 2026, we focused on stabilizing our core business and strengthening the foundation for future long term value creation."
• "We completed strategic, operational and technology initiatives that collectively reduced our cost structure and represent an important foundation for our future."
• "We will continue to focus on operational excellence, driving sustainable long-term results, and delivering value for shareholders."
• "We intend to do this in part through improved customer retention by leveraging our operational improvements, and also by expanding our market footprint through B2B relationships utilizing our membership programs as well as our white-label pharmacy fulfillment services like our recently announced Master Services Agreement with Rural King."

Industry Context

StockSavvy.ai notes that PetMeds' results reflect challenges in the direct-to-consumer pet healthcare sector, particularly concerning prescription medication sales. The decline in sales and increased net loss for the full year are concerning, though the modest sequential improvement in Q4 sales and management's focus on cost reduction and strategic initiatives like B2B partnerships and white-label services are positive signs for future stabilization.

Legal Proceedings

• The company incurred $4.5 million in one-time charges related to a whistleblower investigation.

Stakeholder Impact

• Shareholders: The significant increase in net loss and decrease in cash may negatively impact shareholder value. The company's decision to remain independent after receiving acquisition offers could be viewed positively or negatively depending on shareholder sentiment regarding potential offers.
• Employees: Cost reduction initiatives and strategic shifts may impact employee roles and responsibilities.
• Customers: Focus on improved customer retention and leveraging operational improvements aims to benefit customers.
• Suppliers: Declining sales may lead to reduced order volumes, potentially impacting suppliers.

Next Steps

• Continue to focus on operational excellence.
• Drive sustainable long-term results.
• Deliver value for shareholders.
• Improve customer retention.
• Expand market footprint through B2B relationships and white-label pharmacy fulfillment services.
• Continue to operate as an independent, publicly traded company.
• Remain open to considering future inbound indications of interest for a potential transaction.

Key Dates

Recommendation

While the full-year results are significantly negative, the modest sequential improvement in Q4 sales and management's stated focus on cost reduction and strategic initiatives offer a glimmer of hope for stabilization. The company's decision to remain independent after acquisition offers suggests management believes in its standalone turnaround potential. However, the substantial increase in net loss and decline in cash warrant a cautious 'hold' until operational improvements and strategic initiatives demonstrate tangible positive results.

Keywords

PetMed Express, PETS, 8-K, Financial Results, Fiscal Year 2026, Net Sales, Net Loss, Adjusted EBITDA